Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma

Launched by CHRISTOPHER ZACHARY · Feb 4, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat basal cell carcinoma (BCC), a common type of skin cancer, using a special imaging technique called optical coherence tomography (OCT) to guide laser treatment. The goal is to see if this method can effectively target and remove the cancerous cells while minimizing damage to the surrounding healthy skin. The trial is currently looking for participants, and anyone aged 18 and older who has been diagnosed with BCC and is scheduled for treatment may be eligible to join.

To participate, individuals must be able to understand treatment instructions, and their BCC must not be too large or deeply embedded in the skin. Certain conditions, such as being pregnant or having specific types of lesions, may prevent someone from joining. If they qualify, participants can expect to receive the laser treatment and will need to attend follow-up visits over the next year to monitor their progress. This study offers a chance to contribute to important research that could improve skin cancer treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to understand and carry out subject instructions or be represented by a legally authorized guardian or representative
• • Ages 18 and older
• • Seeks and is scheduled for treatment of a BCC previously confirmed with biopsy
• Exclusion Criteria:
• Any of the following will exclude participation in the study:
• • Inability to understand and/or carry out instructions
• • Patients with a BCC lesion that requires excision. This would include relatively large lesions (\>2.5 cm diameter), lesions that penetrate deep into the skin beyond the depth of the OCT image capture, high risk lesions as defined by the American Academy of Dermatology as recurrent and sclerosing subtype BCC, or metastases.
• • Patients with periocular BCCs which might expose the patient to risk of damage to eyes from the laser.
• • BCCs on legs due to their tendency towards poor wound healing.
• • Pregnancy
• • Patients unable to follow-up for the full 12 months.